Cartesian Therapeutics, Inc.
RNAC
株式のランク
#18421
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
株価
$6.27
最終同期: 2026-10-16
時価総額
$189.70M
変化（1日）
-4.71%
変化（1年）
839.61%
国
US
取引 Cartesian Therapeutics, Inc. (RNAC)
カテゴリー
Healthcare
の時価総額 Cartesian Therapeutics, Inc.(RNAC)
時価総額: $189.70M
October 2026時点で、Cartesian Therapeutics, Inc. の時価総額は $189.70M です。これは、当社のデータによると、Cartesian Therapeutics, Inc. が世界で18421st番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Cartesian Therapeutics, Inc. の時価総額の履歴（2016 から 2026 まで）
